Phenylacetate inhibits growth and modulates cell cycle gene expression in renal cancer cell lines

Anticancer Research

Volumn 23, Issue 2 B, 2003, Pages 1637-1642

  Franco, Omar E ^a   Onishi, Takehisa ^a   Umeda, Yoshiki ^a   Soga, Norihito ^a   Wakita, Toshiaki ^a   Arima, Kiminobu ^a   Yanagawa, Makoto ^a   Sugimura, Yoshiki ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell cycle; p21Cip1; Phenylacetate; Renal cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; ONCOPROTEIN; PHENYLACETIC ACID; PROTEIN KINASE; PROTEIN P21;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, CDC; GROWTH INHIBITORS; HUMANS; KIDNEY NEOPLASMS; NEOPLASM PROTEINS; PHENYLACETATES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0037900497     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Amato R: Modest effect of interferon alfa on metastatic renal-cell carcinoma [letter; comment]. Lancet 353: 6-7, 1999.
2. Vogelzang NJ and Stadler WM: Kidney cancer [see comments]. Lancet 352: 1691-6, 1998.
3. Sandler M, Ruthven CR, Goodwin BL, Lees A and Stern GM: Phenylacetic acid in human body fluids: high correlation between plasma and cerebrospinal fluid concentration values. J Neurol Neurosurg Psychiatry 45(4): 366-8, 1982.
4. Brusilow SW, Danney M, Waber LJ, Batshaw M, Burton B, Levitsky L, Roth K, McKeethren C and Ward J: Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N Engl J Med 310(25): 1630-4, 1984.
5. del Rosario M, Werlin SL and Lauer SJ: Hyperammonemic encephalopathy after chemotherapy. Survival after treatment with sodium benzoate and sodium phenylacetate. J Clin Gastroenterol 25(4): 682-4, 1997.
6. Samid D, Shack S and Sherman LT: Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res 52: 1988-92, 1992a.
7. Samid D, Yeh A and Prasanna P: Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood 80: 1576-81, 1992b.
8. Cinatl J, Mainke M, Weissflog A, Rabenau H, Kornhuber B and Doerr HW: In vitro differentiation of human neuroblastoma cells induced by sodium phenylacetate. Cancer Letters 70: 15-24, 1993.
9. Samid D, Shack S and Myers CE: Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Investig 91: 2288-95, 1993.
10. Cinatl J, Herneiz P, Rabenau H, Hovak M, Benda R, Gumbel HO, Kornhuber B and Doerr HW: Induction of myogenic differentiation in a human rhabdomyosarcoma cell line by phenylacetate. Cancer Letters 78: 41-8, 1994.
11. Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA and Samid D: A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 54: 1690-4, 1994.
12. Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ and Myers CE: Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 75: 2932-8, 1995.
13. Hunter T: Braking the cycle. Cell 75: 839-41, 1993.
14. Sherr CJ: Mammalian G1 cyclins. Cell 73: 1059-65, 1993.
15. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-30, 1995.
16. Sherr CJ and Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes & Development 9: 1149-63, 1995.
17. Sidell N, Wada R, Han G, Chang B, Shack S, Moore T and Samid D: Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells. Int J Cancer 60: 507-14, 1995.
18. Goldstein JL and Brown MS: Regulation of the mevalonate pathway. Nature 343: 425-30, 1990.
19. Pineau T, Hudgins WR, Liu L, Chen LC, Sher T, Gonzalez FJ and Samid D: Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharmacol 52: 659-67, 1996.
20. Bird A: The essentials of DNA methylation. Cell 70: 5-8, 1992.
21. Kebebew E, Wong MG, Siperstein AE, Duh QY and Clark OH: Phenylacetate inhibits growth and vascular endothelial growth factor secretion in human thyroid carcinoma cells and modulates their differentiated function. J Clin Endocrinol Metabolism 84: 2840-7, 1999.
22. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, Nishimoto T, Morgan DO, Franza BR and Roberts JM: Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 257: 1689-94, 1992.
23. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM and Pagano M: Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Molecular & Cellular Biology 15: 2612-24, 1995.
24. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T and Hannon GJ: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552-7, 1995.
25. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE and Wang Y: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-74, 1994.
26. Kastan MB, Canman CE and Leonard CJ: P53, cell cycle control and apoptosis: implications for cancer. Cancer & Metastasis Reviews 14: 3-15, 1995.
27. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW and Elledge SJ: p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells [see comments]. Science 267: 1024-7, 1995.
28. Gorospe M, Shack S, Guyton KZ, Samid D and Holbrook NJ: Upregulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate. Cell Growth & Differentiation 7: 1609-15, 1996.
29. Onishi T, Yamakawa K, Franco OE, Suzuki R and Kawamura J: p27Kip1 is the key mediator of phenylacetate-induced cell cycle arrest in human prostate cancer cells. Anticancer Res 20: 3075-81, 2000.